AVONEX

País: Israel

Idioma: inglés

Fuente: Ministry of Health

Ingredientes activos:

INTERFERON BETA 1A 30 MCG/VIAL

Disponible desde:

MEDISON PHARMA LTD

Código ATC:

L03AB07

formulario farmacéutico:

POWDER FOR SOLUTION FOR INJECTION

Vía de administración:

I.M

Fabricado por:

BIOGEN IDEC LTD, UK

Grupo terapéutico:

INTERFERON BETA-1A

indicaciones terapéuticas:

Avonex is indicated for the treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. Avonex is also indicated for the treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of MRI abnormalities characteristic of MS and if they are determined to be at high risk of developing clinically definite multiple sclerosis. Safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

Fecha de autorización:

2011-11-01